A 61-year-old woman was diagnosed as having myelodysplastic syndrome (MDS), refractory anemia with ringed sideroblasts (RARS) in 1997. She required increasingly frequent red cell transfusions which by October 2002 were weekly, despite no increase in blasts or cytogenetic abnormalities in the marrow. Owing to the strong wishes of the patient and her family, we considered a reducedintensity stem cell transplantation (SCT).
Results of the HLA haplotypes of the family members were: patient A24 B7 DR1/A26 B7 DR1; sister A24 B7 DR1/A2 B60 DR12; mother A2 B60 DR12/A26 B7 DR1. Based on the recently reported concept of feto-maternal tolerance, 1,2 her sister, who had noninherited maternal antigen (HLA-26) chimerism in peripheral blood cells, 3 was selected as a HLA-haploidentical donor. The frequency of NIMA-A26 in the donor's blood was estimated to be 1 in 1000 using an HLA nested PCR method. Prior to transplant, the patient had mild pulmonary hypertension and tricuspid regurgitation with preserved cardiac function. Ultrasonography indicated mild hepatomegaly and increased liver density, suggesting hemochromatosis. She had received a total of 42 red cell transfusions before transplant.
She underwent SCT in January 2003, with a conditioning regimen consisting of fludarabine at a daily dose of 30 mg/m 2 on days À8 to À3 (total dose 180 mg/m 2 ) and busulfan at a daily dose of 4 mg/kg on days À6 and À5 (total dose 8 mg/ kg). The patient then received her sister's unmanipulated granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (total number of CD34-positive cells was 2.38 Â 10 6 /kg). Tacrolimus was initially administered from day À1 at a dose of 0.02 mg/kg/day as a continuous infusion, and short-term methotrexate was administered on days 1, 3, and 5 at doses of 10, 5, and 5 mg/m 2 , respectively, as graftversus-host disease (GVHD) prophylaxis. Severe early toxicities such as mucositis or infections were not observed. The neutrophil count did not decrease below 0.5 Â 10 9 /l after transplant, and platelet engraftment was observed on day 14. Transient mild liver dysfunction occurred on day 14. Grade II acute GVHD (skin stage 1 and gut stage 1) occurred on day 17 and methylprednisolone at a dose of 2 mg/kg/day was initiated. Complete donor chimerism was confirmed by analysis of microsatellite polymorphism of human betaactin-related pseudogene 6 (ACTBP2) on day 29. Since day 100, she has been free from transfusion requirements and has no additional complications or acute or chronic GVHD.
Although recent progress with reduced intensity regimens has expanded patient eligibility for transplant, 4 many patients still lack matched donors. The recently reported concept of feto-maternal tolerance 1,2 may overcome this donor limitation; however, the possibility of graft failure, severe GVHD and organ failure remain, especially with reduced intensity regimens. Nevertheless, Umeda et al 5 reported favorable results in a 16-year-old girl with acute lymphoblastic leukemia, who received non-T-cell-depleted SCT from her haploidentical mother, using a reducedintensity regimen with intensive GVHD prophylaxis. Our case is the first report of reduced-intensity haploidentical SCT for an elderly patient based on feto-maternal tolerance. While further evaluation is needed, based on the results of previous haploidentical SCT, 6 feto-maternal immunological tolerance may nonetheless lead to a high likelihood of engraftment and control of GVHD in highrisk elderly patients lacking matched donors, who are appropriate candidates to undergo a haploidentical reduced-intensity transplant.
